The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Factors to consider when choosing a treatment option for patients with CLL
Piers Patten, MBChB, MRCP, FRCPath, PhD, King’s College London, London, UK, discusses the complex issue of selecting a therapy approach for patients with chronic lymphocytic leukemia (CLL). As the number of available treatment options has increased in recent years, physicians now have several agents to choose from. Dr Patten highlights that, when selecting a treatment, there is a need to consider the nature of the patient’s disease, their medical history and comorbidities, and, importantly, their preferences. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
